Exploring Undervalued Opportunities: 3 SEHK Stocks With Intrinsic Discounts Ranging From 27.6% To 41.4%

In This Article:

Amidst a backdrop of fluctuating global markets, the Hong Kong stock market presents intriguing opportunities, evidenced by its recent modest gains. As investors seek value in a landscape marked by mixed economic signals, identifying undervalued stocks becomes a prudent strategy to explore potential growth avenues.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name

Current Price

Fair Value (Est)

Discount (Est)

Bairong (SEHK:6608)

HK$9.24

HK$15.77

41.4%

China Cinda Asset Management (SEHK:1359)

HK$0.72

HK$1.29

44.2%

Zijin Mining Group (SEHK:2899)

HK$16.40

HK$28.83

43.1%

Zylox-Tonbridge Medical Technology (SEHK:2190)

HK$10.14

HK$19.04

46.7%

Super Hi International Holding (SEHK:9658)

HK$14.22

HK$25.84

45%

REPT BATTERO Energy (SEHK:666)

HK$14.00

HK$27.28

48.7%

Zhaojin Mining Industry (SEHK:1818)

HK$13.20

HK$24.93

47%

Innovent Biologics (SEHK:1801)

HK$39.50

HK$72.75

45.7%

CGN Mining (SEHK:1164)

HK$2.58

HK$4.83

46.6%

Vobile Group (SEHK:3738)

HK$1.22

HK$2.11

42.3%

Click here to see the full list of 42 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of from the screener

Genscript Biotech

Overview: Genscript Biotech Corporation is an investment holding company that manufactures and sells life science research products and services across the United States, Europe, China, Japan, other Asia Pacific regions, and globally, with a market capitalization of approximately HK$17.88 billion.

Operations: The company's revenue is segmented into Cell Therapy (HK$285.14 million), Operation Unit (HK$53.15 million), Biologics Development Services (HK$109.49 million), Life Science Services and Products (HK$412.91 million), and Industrial Synthetic Biology Products (HK$43.05 million).

Estimated Discount To Fair Value: 35%

Genscript Biotech, trading at HK$8.75, is perceived as undervalued based on a DCF valuation with its fair value estimated at HK$13.47. The company's revenue is expected to grow by 37.2% annually, outpacing the Hong Kong market's 7.8%. Although currently unprofitable, it is forecasted to reach profitability within three years with earnings potentially increasing by 97.94% per year. Recent board and executive changes alongside strategic product launches like the FLASH Gene service could influence future performance and governance stability.

SEHK:1548 Discounted Cash Flow as at Jun 2024

Bairong

Overview: Bairong Inc. is a provider of cloud-based AI turnkey services in China, with a market capitalization of approximately HK$4.25 billion.